Particle.news
Download on the App Store
4 ARTICLES
·
3h ago

Law Firms Compete to Lead Hims & Hers Investor Lawsuits

Three plaintiff firms are urging investors to file lead-plaintiff motions by August 25, 2025, in shareholder suits alleging Hims & Hers misled the market over its terminated Novo Nordisk deal.

Hims deadline notice: rosen, recognized investor counsel, encourages hims & hers health, inc. investors with losses in excess of $100k to secure counsel before important august 25 deadline in...

Overview

  • Novo Nordisk terminated its collaboration with Hims & Hers on June 23, 2025, accusing the telehealth company of deceptive marketing and selling unapproved semaglutide knockoffs that risked patient safety.
  • The termination announcement drove a 34.6% plunge in Hims & Hers’ share price and prompted multiple federal securities class-action complaints in the Northern District of California.
  • Complaints Sookdeo v. Hims & Hers (No. 25-cv-05315) and Yaghsizian v. Hims & Hers (No. 25-cv-05321) allege violations of the Securities Exchange Act based on misleading statements about Wegovy distribution and compounded drug approvals.
  • Robbins Geller Rudman & Dowd, Faruqi & Faruqi and the Rosen Law Firm have filed early-stage claims and are soliciting investors to serve as lead plaintiff.
  • Investors who bought Hims & Hers securities between April 29 and June 23 have until August 25, 2025, to move for lead-plaintiff status under PSLRA procedures.